Venture activity in China’s life‑science sector accelerated with multiple large financings announced this week, including seven‑figure and nine‑figure rounds that signal continued appetite for biologics and platform startups. BioCentury reported that D3 Bio and Sanegene each raised $100M+ rounds, and D3 Bio separately closed a $108M Series B to advance its KRAS G12C candidate to Phase III. Large cheques are concentrated in oncology, genomics and long‑acting metabolic therapeutics, reflecting both domestic fundraising capacity and interest from global investors. The fresh capital will underwrite late‑stage trials and regional expansion, and may intensify competition for global partnerships and licensing deals with Western pharmaceutical companies. The funding wave also pressures smaller local players to consolidate or seek strategic alliances, while global biopharmas are watching for acquisition opportunities that bridge discovery platforms and China market access.